| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $1,757 | 1 | 100 |
| Broadrick Dale | 10 percent owner | 0 | $0 | 1 | $1,757 | $-1,757 |
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Over the last 12 months, insiders at BioRestorative Therapies, Inc. have bought $0 and sold $1,757 worth of BioRestorative Therapies, Inc. stock.
On average, over the past 5 years, insiders at BioRestorative Therapies, Inc. have bought $646,572 and sold $5,759 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,600 shares for transaction amount of $8,250 was made by Silva Francisco (VP of Research and Development) on 2024‑04‑09.
| 2024-10-28 | Sale | Broadrick Dale | 10 percent owner | 1,112 0.0157% | $1.58 | $1,757 | +7.59% | |
| 2024-04-09 | Silva Francisco | VP of Research and Development | 6,600 0.0952% | $1.25 | $8,250 | +25.78% | ||
| 2024-04-08 | Silva Francisco | VP of Research and Development | 1,708 0.0228% | $1.16 | $1,979 | +25.00% | ||
| 2024-02-09 | Broadrick Dale | 10 percent owner | 86,041 1.4895% | $1.32 | $113,574 | +11.85% | ||
| 2024-02-08 | Broadrick Dale | 10 percent owner | 157,585 2.6821% | $1.30 | $204,508 | +17.58% | ||
| 2024-02-08 | Broadrick Dale | 10 percent owner | 73,959 1.2124% | $1.25 | $92,449 | +17.58% | ||
| 2024-02-07 | Broadrick Dale | 10 percent owner | 36,374 0.6583% | $1.38 | $50,196 | +5.63% | ||
| 2023-12-01 | Sale | Broadrick Dale | 10 percent owner | 250 0.0053% | $1.88 | $469 | -15.68% | |
| 2023-11-27 | Sale | Broadrick Dale | 10 percent owner | 278 0.0059% | $1.89 | $525 | -17.37% | |
| 2023-09-15 | Broadrick Dale | 10 percent owner | 10,000 0.213% | $1.66 | $16,600 | -2.69% | ||
| 2023-09-15 | ALSTODT LANCE | President, CEO, COB | 2,200 0.048% | $1.70 | $3,740 | -2.69% | ||
| 2023-09-14 | Broadrick Dale | 10 percent owner | 10,000 0.2062% | $1.54 | $15,400 | +1.88% | ||
| 2023-09-13 | ALSTODT LANCE | President, CEO, COB | 800 0.0161% | $1.53 | $1,226 | +8.33% | ||
| 2023-09-07 | Broadrick Dale | 10 percent owner | 2,000 0.044% | $1.86 | $3,720 | -13.76% | ||
| 2023-09-06 | ALSTODT LANCE | President, CEO, COB | 2,887 0.0638% | $1.96 | $5,659 | -14.21% | ||
| 2023-08-31 | Silva Francisco | VP of Research and Development | 4,954 0.1071% | $2.22 | $10,998 | -25.45% | ||
| 2023-07-28 | Broadrick Dale | 10 percent owner | 500 0.016% | $2.89 | $1,445 | -39.82% | ||
| 2023-07-27 | Broadrick Dale | 10 percent owner | 1,000 0.031% | $2.80 | $2,800 | -39.22% | ||
| 2023-07-25 | ALSTODT LANCE | President, CEO, COB | 4,200 0.1134% | $2.44 | $10,248 | -29.22% | ||
| 2023-03-31 | Silva Francisco | VP of Research and Development | 747 0.0216% | $3.56 | $2,659 | -42.35% |
| Broadrick Dale | 10 percent owner | 445933 5.942% | $758,086.10 | 79 | 4 | <0.0001% |
| Westbury Trust | 10 percent owner | 3115000 41.5069% | $5.3M | 1 | 0 | |
| Desmarais John M | 455000 6.0628% | $773,500.00 | 2 | 0 | ||
| ALSTODT LANCE | President, CEO, COB | 189505 2.5251% | $322,158.50 | 33 | 0 | <0.0001% |
| Silva Francisco | VP of Research and Development | 155759 2.0755% | $264,790.30 | 21 | 1 | <0.0001% |
| Tonna Paul Jude | director | 123850 1.6503% | $210,545.00 | 4 | 0 | |
| Weinreb Mark | CEO and Chairman of the Board | 117000 1.559% | $198,900.00 | 5 | 0 | |
| Swiader Joseph B | director | 100000 1.3325% | $170,000.00 | 1 | 0 | |
| CATELL ROBERT B | director | 80866 1.0775% | $137,472.20 | 3 | 0 | |
| Radov A. Jeffrey | director | 24500 0.3265% | $41,650.00 | 4 | 0 | |
| Ryan Charles S. | director | 16250 0.2165% | $27,625.00 | 2 | 0 | |
| Kristal Robert Eugene | Chief Financial Officer | 7994 0.1065% | $13,589.80 | 3 | 0 | <0.0001% |
| Clark Mandy D. | VP of Operations | 0 0% | $0 | 0 | 1 |
BioRestorative Therapies, Inc. (BRTX) | $1,848,072 | 66 | -14.67% | $12.76M |
$1,443,732 | 36 | 10.14% | $11.76M | |
$95,303,339 | 30 | -13.78% | $12.66M | |
$226,127 | 22 | -27.62% | $14.29M | |
$547,862 | 19 | -29.82% | $12.25M | |
$53,355 | 19 | -41.05% | $11.32M | |
$37,197,670 | 19 | -48.36% | $10.85M | |
$114,371,781 | 18 | -1.31% | $12.1M | |
$2,553,853 | 17 | 16.69% | $14.99M | |
$122,973 | 15 | -26.96% | $14.05M | |
$39,336,371 | 14 | -17.87% | $13.57M | |
$941,975 | 12 | -10.74% | $10.98M | |
$20,715,938 | 10 | -42.51% | $15.67M | |
$36,538,405 | 10 | -21.99% | $15.91M | |
$70,584,874 | 10 | 3.97% | $16.18M | |
$2,060,158 | 5 | -21.35% | $15.77M | |
$82,858 | 3 | -15.88% | $10.94M | |
$31,190 | 2 | -14.18% | $14.2M | |
$5,512,500 | 1 | -7.91% | $12.7M |
| Increased Positions | 10 | +90.91% | 27,774 | +9.79% |
| Decreased Positions | 2 | -18.18% | 29,432 | -10.38% |
| New Positions | 2 | New | 13 | New |
| Sold Out Positions | <1 | Sold Out | 21,481 | Sold Out |
| Total Postitions | 19 | +72.73% | 281,913 | -0.58% |
| Geode Capital Management, Llc | $101.00 | 0.68% | 54,722 | -984 | -1.77% | 2024-12-31 |
| Stonex Group Inc. | $92.00 | 0.63% | 50,100 | 0 | 0% | 2024-12-31 |
| Wealth Alliance | $74.00 | 0.5% | 40,000 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $51.00 | 0.34% | 27,500 | +10,000 | +57.14% | 2024-12-31 |
| Citadel Advisors Llc | $40.00 | 0.27% | 21,481 | +21,481 | New | 2024-12-31 |
| Vanguard Group Inc | $38.00 | 0.26% | 20,472 | 0 | 0% | 2024-12-31 |
| State Street Corp | $38.00 | 0.26% | 20,459 | 0 | 0% | 2024-12-31 |
| Us Financial Advisors, Llc | $32.00 | 0.21% | 17,142 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $30.00 | 0.2% | 16,297 | +15,604 | +2,251.66% | 2024-12-31 |
| Newman Dignan & Sheerar, Inc. | $21.00 | 0.14% | 11,522 | 0 | 0% | 2025-03-31 |